Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Clinical trial NCT05394103 · RECRUITING

Trial details

NCT number: NCT05394103
Sponsor: Qurient Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Cancer Metastatic Cancer

Start date: 2022-08-30
Primary completion: 2025-12-30
Enrollment: 130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.